Alnylam Pharmaceuticals | ALNY - Los Gastos Financieros De La Deuda

Precio De Mercado
328.40
Cambio Diario
-0.30 -0.09%
Mensual
-1.36%
Anual
21.17%
Q1 Expectativa
318.90




Los Gastos Financieros De La Deuda Cambio Fecha
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Amgen USD 653M 32M 2025-12
Arrowhead Research USD 22.5M 811K 2025-12
BioCryst Pharmaceuticals USD 14.14M 5.53M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Moderna USD 12.14B 12.13B 2025-09
Neurocrine Biosciences USD 1.1M 0 2024-03
Novartis USD 281M 8M 2025-09
PTC Therapeutics USD 50.58M 2.59B 2025-12
Regeneron Pharmaceuticals USD 12.2M 7.1M 2025-12
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR -25M 99.78M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Takeda JPY 123.63B 40.49B 2025-12
Tectonic Therapeutic USD 12K 276.99M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 311K 2025-12